Prevalence of metabolic syndrome in HIV-infected patients naive to antiretroviral therapy or receiving a first-line treatment

References

• Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada, from 1984 to 2003. HIV Med. 2005;6:99–106.10.1111/hiv.2005.6.issue-2
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, Luz PM, Pacheco AG, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to Non-AIDS related conditions in the HAART era. PLoS ONE. 2013;8:e59768.10.1371/journal.pone.0059768
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58.10.1097/00002030-199807000-00003
   PubMed Web of Science ®Google Scholar
• Krishnan S, Schouten JT, Atkinson B, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr. 2012;61:381–389.10.1097/QAI.0b013e3182690e3c
   PubMed Web of Science ®Google Scholar
• Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745–2749.10.2337/diacare.28.11.2745
   PubMed Web of Science ®Google Scholar
• Grundy SM. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752.10.1161/CIRCULATIONAHA.105.169404
   PubMed Web of Science ®Google Scholar
• Ford ES, Cunningham TJ, Mercado CI. Lung function and metabolic syndrome: findings of National Health and Nutrition Examination Survey 2007–2010. J Diabetes. 2014;6:603–613.10.1111/jdb.2014.6.issue-6
   PubMed Web of Science ®Google Scholar
• Miccoli R, Bianchi C, Odoguardi L, et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis. 2005;15:250–254.10.1016/j.numecd.2004.09.002
   PubMed Web of Science ®Google Scholar
• Kastorini CM, Panagiotakos DB, Georgousopoulou EN, et al. Metabolic syndrome and 10-year cardiovascular disease incidence: the ATTICA study. Nutr Metab Cardiovasc Dis. 2016;26:223–231.10.1016/j.numecd.2015.12.010
   PubMed Web of Science ®Google Scholar
• Estrada V, Martínez-Larrad MT, González-Sánchez JL, et al. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism. 2006;55:940–945.10.1016/j.metabol.2006.02.024
   PubMed Web of Science ®Google Scholar
• Worm SW, Friis-Møller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS. 2010;24:427–435.10.1097/QAD.0b013e328334344e
   PubMed Web of Science ®Google Scholar
• Mondy K, Overton ET, Grubb J, et al. Metabolic syndrome in HIV-infected patients from an urban, Midwestern US outpatient population. Clin Infect Dis. 2007;44:726–734.10.1086/511679
   PubMed Web of Science ®Google Scholar
• Adeyemi O, Rezai K, Bahk M, et al. Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort. AIDS Patient Care STDs. 2008;22:941–945.10.1089/apc.2008.0119
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl 1):S8–S16.
   PubMed Web of Science ®Google Scholar
• WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization; 2000.
   Google Scholar
• Alberti KG, Zimmet P, Shaw J. IDF, epidemiology task force consensus group. The metabolic syndrome – a new worldwide definition. Lancet. 2005;366:1059–1062.10.1016/S0140-6736(05)67402-8
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006;43:458–466.10.1097/01.qai.0000243093.34652.41
   PubMed Web of Science ®Google Scholar
• Price J, Hoy J, Ridley E, et al. Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men. Sex Health. 2015;12:240–248.
   PubMed Web of Science ®Google Scholar
• Sobieszczyk ME, Hoover DR, Anastos K, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr. 2008;48:272–280.10.1097/QAI.0b013e31817af461
   PubMed Web of Science ®Google Scholar
• Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010;2:180–193.10.1111/jdb.2010.2.issue-3
   PubMed Web of Science ®Google Scholar
• Muyanja D, Muzoora C, Muyingo A, Muyindike W, Siedner MJ. High prevalence of metabolic syndrome and cardiovascular disease risk among people with HIV on stable ART in southwestern Uganda. AIDS Patient Care STDs. 2016;30:4–10.10.1089/apc.2015.0213
   PubMed Web of Science ®Google Scholar
• Obirikorang C, Quaye L, Osei-Yeboah J, et al. Prevalence of metabolic syndrome among HIV-infected patients in Ghana: a cross-sectional study. Niger Med J. 2016;57:86–90.10.4103/0300-1652.182082
   PubMedGoogle Scholar
• Nguyen KA, Peer N, Mills EJ, Kengne AP. A meta-analysis of the metabolic syndrome prevalence in the global HIV-infected population. PLOS ONE. 2016;11:e0150970.10.1371/journal.pone.0150970
   PubMed Web of Science ®Google Scholar
• Krishnan S, Schouten JT, Atkinson B, et al. Changes in metabolic syndrome status after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68:73–80.10.1097/QAI.0000000000000397
   PubMed Web of Science ®Google Scholar
• Wu PY, Hung CC, Liu WC, et al. Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. J Antimicrob Chemother. 2012;67:1001–1009.10.1093/jac/dkr558
   PubMed Web of Science ®Google Scholar
• Alencastro PR, Fuchs SC, Wolff FH, et al. Independent predictors of metabolic syndrome in HIV-infected patients. AIDS Patient Care STDs. 2011;25:627–634.10.1089/apc.2010.0360
   PubMed Web of Science ®Google Scholar
• Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15:F11–F18.10.1097/00002030-200105040-00001
   PubMed Web of Science ®Google Scholar
• Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-seronegative men. AIDS. 2004;18:641–649.10.1097/00002030-200403050-00008
   PubMed Web of Science ®Google Scholar
• Elgalib A, Aboud M, Kulasegaram R, et al. The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. Curr Med Res Opin. 2011;27:63–69.10.1185/03007995.2010.537212
   PubMed Web of Science ®Google Scholar
• Young J, Glass TR, Bernasconi E, et al. Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. J Clin Epidemiol. 2009;62:632–641.10.1016/j.jclinepi.2008.07.015
   PubMed Web of Science ®Google Scholar
• Franssen R, Sankatsing RR, Hassink E, et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol. 2009;29:1336–1341.10.1161/ATVBAHA.109.192088
   PubMed Web of Science ®Google Scholar
• Mangili A, Jacobson DL, Gerrior J, Polak JF, Gorbach SL, Wanke CA. Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis. 2007;44:1368–1374.10.1086/516616
   PubMed Web of Science ®Google Scholar
• Fitch KV, Lo J, Abbara S, et al. Increased coronary artery calcium score and non-calcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. J Acquir Immune Defic Syndr. 2010;55:495–499.10.1097/QAI.0b013e3181edab0b
   PubMed Web of Science ®Google Scholar
• Worm SW, Sabin CA, Reiss P, et al. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2009;32:474–480.10.2337/dc08-1394
   PubMed Web of Science ®Google Scholar
• Seaberg EC, Muñoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19:953–960.10.1097/01.aids.0000171410.76607.f8
   PubMed Web of Science ®Google Scholar
• Baekken M, Os I, Sandvik L, Oektedalen O. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens. 2008;26:2126–2133.10.1097/HJH.0b013e32830ef5fb
   PubMed Web of Science ®Google Scholar
• Martin-Iguacel R, Negredo E, Peck R, Friis-Møller N. Hypertension is a key feature of the metabolic syndrome in subjects aging with HIV. Curr Hypertens Rep. 2016;18:46.10.1007/s11906-016-0656-3
   PubMed Web of Science ®Google Scholar
• Welty FK, Alfaddagh A, Elajami TK. Targeting inflammation in metabolic syndrome. Transl Res. 2016;167:257–280.10.1016/j.trsl.2015.06.017
   PubMed Web of Science ®Google Scholar
• Nasi M, De Biasi S, Gibellini L, et al. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol. 2017;187:44–52.10.1111/cei.12814
   PubMed Web of Science ®Google Scholar
• Calza L, Masetti G, Piergentili B, et al. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection. Int J STD AIDS. 2011;22:43–45.10.1258/ijsa.2010.010256
   PubMed Web of Science ®Google Scholar